Patent Overview
A formulation dossier linked to liver-disease and oncology-related research contexts in local materials.
Indication: Liver Disease Research, Supportive Research on Tumors, Discussion on Joint Development
Principle and Advantage
The Soft Liver and Anti-Bloating Pill is best defined as a ‘research-oriented asset at the intersection of liver disease and liver cancer.’ For investors, what is most easily understood is not the single formula itself, but rather the large HCC market it targets and the continuously evolving landscape of systemic therapies.
Scientific Basis: Integration of Syndrome and Disease, Simultaneous Use of Tonifying and Removing Pathogenic Factors, Compilation of Liver Disease Research Materials
- This asset can be positioned within the broader narrative of the 'liver disease–cancer crossover market,' rather than being limited to a single formulation description.
- The market is sufficiently mature, making it easier for partners and investors to position its value within the existing drug landscape.
- It is suitable for presenting simultaneously to pharmaceutical BD teams, regional commercialization partners, and liver disease research teams.
Market Context
Market reference：US liver cancer cases (2026): 42,340; Global cases forecast by 2040: 1.4M
- The liver cancer market is both large and mature, making its business logic easy for investors to quickly grasp.
- Newly approved regimens are concentrated in immunotherapy/combinatorial therapy, suggesting that there is still room for portfolio assets.
- The intersection of liver disease and tumors provides an opportunity to tell the story of ‘regionalization + combinatorial approach + data-driven assets.’
Lenvima (lenvatinib)
Multikinase inhibitor · First-line treatment for unresectable HCC.
This represents a mature targeted therapy pathway, with a high level of market education already achieved.
Imjudo + Imfinzi
CTLA-4 + PD-L1 immunotherapy combination · Systemic treatment combinations for unresectable HCC.
Indicates that HCC is shifting toward immuno-combination therapy.
Opdivo + Yervoy
PD-1 + CTLA-4 immunotherapy combination · First-line treatment for unresectable or metastatic HCC.
The latest round of approvals demonstrates that major pharmaceutical companies are still ramping up their efforts in the HCC market.
Related Books
Research on Pei Zhengxue's Formulation Series
Research on Pei Zhengxue's Series of Formulas and Medicines / Compiled by Zhang Chouchou — Lanzhou: Gansu Science and Te.
Collected Medical Experience of Pei Zhengxue
Collected Medical Experiences of Professor Pei Zhengxue / Compiled and authored by Pei Zhengxue Lanzhou: Gansu Science a.
Cooperation
Suitable for organizing liver disease-related materials, mapping clinical and experimental information, and conducting early-stage co-development discussions.
This page is for academic exchange and collaboration reference and does not constitute medical advice, product marketing, or efficacy claims.